IGF1 and neoplasm: Notably, concurrent inhibition of IGF-1/PI3K and CSF-1R using Linsitinib (OSI906) and Sotuletinib (BLZ945) has shown promising results, significantly extending median survival in preclinical models until tumor recurrence [32].